NCCN Guidelines Insights: Bladder Cancer, Version 5.2018

Restricted access

The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.

Provided content development and/or authorship assistance.

Please NoteThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. The NCCN Guidelines® Insights highlight important changes in the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further understanding of these changes by summarizing salient portions of the panel's discussion, including the literature reviewed.The NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their applications or use in any way.The full and most current version of these NCCN Guidelines is available at NCCN.org.© National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
  • 1.

    SiegelRLMillerKDJemalA. Cancer statistics, 2018. CA Cancer J Clin2018;68:730.

  • 2.

    Cancer Stat Facts: Bladder Cancer. National Cancer Institute. Bethesda, MD. Available at: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed January 24 2018.

    • Search Google Scholar
    • Export Citation
  • 3.

    AminMBEdgeSBGreeneF eds. AJCC Cancer Staging Manual8th ed.New York, NY: Springer International Publishing; 2017.

  • 4.

    EdgeSBByrdDRComptonCC. AJCC Cancer Staging Manual7th ed.New York, NY: Springer; 2010.

  • 5.

    von der MaaseHSengelovLRobertsJT. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol2005;23:46024608.

    • Search Google Scholar
    • Export Citation
  • 6.

    TarinTVPowerNEEhdaieB. Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol2012;61:10251030.

    • Search Google Scholar
    • Export Citation
  • 7.

    SteinJPLieskovskyGCoteR. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol2001;19:666675.

    • Search Google Scholar
    • Export Citation
  • 8.

    GhoneimMAAbdel-LatifMel-MekreshM. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol2008;180:121127.

    • Search Google Scholar
    • Export Citation
  • 9.

    BajorinDFDoddPMMazumdarM. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol1999;17:31733181.

    • Search Google Scholar
    • Export Citation
  • 10.

    MeijerRPMertensLSvan RhijnBW. Induction chemotherapy followed by surgery in node positive bladder cancer. Urology2014;83:134139.

  • 11.

    AzumaHInamotoTTakaharaK. The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis. Int J Oncol2014;44:18951903.

    • Search Google Scholar
    • Export Citation
  • 12.

    StanikMPoprachAMacikD. Clinically node-positive bladder cancer: oncological results of induction chemotherapy and consolidative surgery. Neoplasma2018;65:287291.

    • Search Google Scholar
    • Export Citation
  • 13.

    Zargar-ShoshtariKZargarHLotanY. A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy. J Urol2016;195:5359.

    • Search Google Scholar
    • Export Citation
  • 14.

    GrossmanHBNataleRBTangenCM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med2003;349:859866.

    • Search Google Scholar
    • Export Citation
  • 15.

    SternbergCNde MulderPHSchornagelJH. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol2001;19:26382646.

    • Search Google Scholar
    • Export Citation
  • 16.

    von der MaaseHHansenSWRobertsJT. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol2000;18:30683077.

    • Search Google Scholar
    • Export Citation
  • 17.

    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Eur Urol2005;48:202205; discussion 205–206.

    • Search Google Scholar
    • Export Citation
  • 18.

    Advanced Bladder Cancer Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol2005;48:189199; discussion 199–201.

    • Search Google Scholar
    • Export Citation
  • 19.

    ZaghloulMSAwwadHKAkoushHH. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys1992;23:511517.

    • Search Google Scholar
    • Export Citation
  • 20.

    ShipleyWUWinterKAKaufmanDS. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol1998;16:35763583.

    • Search Google Scholar
    • Export Citation
  • 21.

    EfstathiouJASpiegelDYShipleyWU. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol2012;61:705711.

    • Search Google Scholar
    • Export Citation
  • 22.

    KaufmanDSWinterKAShipleyWU. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist2000;5:471476.

    • Search Google Scholar
    • Export Citation
  • 23.

    HaganMPWinterKAKaufmanDS. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys2003;57:665672.

    • Search Google Scholar
    • Export Citation
  • 24.

    KaufmanDSWinterKAShipleyWU. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology2009;73:833837.

    • Search Google Scholar
    • Export Citation
  • 25.

    MitinTHuntDShipleyWU. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol2013;14:863872.

    • Search Google Scholar
    • Export Citation
  • 26.

    CoppinCMGospodarowiczMKJamesK. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol1996;14:29012907.

    • Search Google Scholar
    • Export Citation
  • 27.

    HoussetMMaulardCChretienY. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol1993;11:21502157.

    • Search Google Scholar
    • Export Citation
  • 28.

    JamesNDHussainSAHallE. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med2012;366:14771488.

  • 29.

    MakRHZietmanALHeneyNM. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int2008;102:13451353.

  • 30.

    RodelCGrabenbauerGGKuhnR. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol2002;20:30613071.

    • Search Google Scholar
    • Export Citation
  • 31.

    ShipleyWUKaufmanDSZehrE. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology2002;60:6267; discussion 67–68.

    • Search Google Scholar
    • Export Citation
  • 32.

    HaqueWVermaVButlerEBTehBS. Chemotherapy versus chemoradiation for node-positive bladder cancer: practice patterns and outcomes from the National Cancer Data Base. Bladder Cancer2017;3:283291.

    • Search Google Scholar
    • Export Citation
  • 33.

    HermansTJFransen van de PutteEEHorenblasS. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer—results of a nationwide population-based study. Eur J Cancer2016;69:18.

    • Search Google Scholar
    • Export Citation
  • 34.

    De SantisMBellmuntJMeadG. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol2012;30:191199.

    • Search Google Scholar
    • Export Citation
  • 35.

    BellmuntJTheodoreCDemkovT. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol2009;27:44544461.

    • Search Google Scholar
    • Export Citation
  • 36.

    KaufmanDRaghavanDCarducciM. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol2000;18:19211927.

    • Search Google Scholar
    • Export Citation
  • 37.

    SternbergCNde MulderPSchornagelJH. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer2006;42:5054.

    • Search Google Scholar
    • Export Citation
  • 38.

    De SantisMBellmuntJMeadG. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. J Clin Oncol2009;27:56345639.

    • Search Google Scholar
    • Export Citation
  • 39.

    BalarAVGalskyMDRosenbergJE. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet2017;389:6776.

    • Search Google Scholar
    • Export Citation
  • 40.

    BalarAVCastellanoDO'DonnellPH. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol2017;18:14831492.

    • Search Google Scholar
    • Export Citation
  • 41.

    US Food & Drug Administration. FDA Alerts Health Care Professionals and Oncology Clinical Investigators About an Efficacy Issue Identified in Clinical Trials for Some Patients Taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as Monotherapy to Treat Urothelial Cancer With Low Expression of PD-L1. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm608075.htm. Updated June202018. Accessed June 27 2018.

    • Search Google Scholar
    • Export Citation
  • 42.

    BellmuntJde WitRVaughnDJ. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med2017;376:10151026.

  • 43.

    RosenbergJEHoffman-CensitsJPowlesT. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet2016;387:19091920.

    • Search Google Scholar
    • Export Citation
  • 44.

    PowlesTDuranIvan der HeijdenMS. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet2018;391:748757.

    • Search Google Scholar
    • Export Citation
  • 45.

    SharmaPRetzMSiefker-RadtkeA. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol2017;18:312322.

    • Search Google Scholar
    • Export Citation
  • 46.

    SharmaPCallahanMKBonoP. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol2016;17:15901598.

    • Search Google Scholar
    • Export Citation
  • 47.

    MassardCGordonMSSharmaS. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol2016;34:31193125.

    • Search Google Scholar
    • Export Citation
  • 48.

    PowlesTO'DonnellPHMassardC. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol2017;3:e172411.

    • Search Google Scholar
    • Export Citation
  • 49.

    ApoloABInfanteJRBalmanoukianA. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol2017;35:21172124.

    • Search Google Scholar
    • Export Citation
  • 50.

    PatelMREllertonJInfanteJR. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol2018;19:5164.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 4 4 0
Full Text Views 3267 3267 261
PDF Downloads 845 845 67
EPUB Downloads 0 0 0